CL2011001937A1 - Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad. - Google Patents

Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.

Info

Publication number
CL2011001937A1
CL2011001937A1 CL2011001937A CL2011001937A CL2011001937A1 CL 2011001937 A1 CL2011001937 A1 CL 2011001937A1 CL 2011001937 A CL2011001937 A CL 2011001937A CL 2011001937 A CL2011001937 A CL 2011001937A CL 2011001937 A1 CL2011001937 A1 CL 2011001937A1
Authority
CL
Chile
Prior art keywords
humans
animals
lactobacillus rhamnosus
obesity
strain
Prior art date
Application number
CL2011001937A
Other languages
English (en)
Inventor
Fabrizio Arigoni
Christian Darimont-Nicolau
Catherine Mace
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2011001937A1 publication Critical patent/CL2011001937A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE LACTOBACILLUS RHAMNOSUS CNCM 1-4096, PARA APOYAR LA PÉRDIDA DE PESO Y/O MANTENIMIENTO DEL PESO EN HUMANOS Y/O ANIMALES. MICROORGANISMO DE LA CEPA LACTOBACILLUS RHAMNOSUS DEPOSITADO BAJO EL NÚMERO DE ACCESO CNCM I-4096.
CL2011001937A 2009-02-10 2011-08-10 Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad. CL2011001937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09152435A EP2216035A1 (en) 2009-02-10 2009-02-10 Lactobacillus rhamnosus CNCM I-4096 and weight control

Publications (1)

Publication Number Publication Date
CL2011001937A1 true CL2011001937A1 (es) 2012-01-20

Family

ID=40762310

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001937A CL2011001937A1 (es) 2009-02-10 2011-08-10 Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.

Country Status (8)

Country Link
US (1) US8318150B2 (es)
EP (2) EP2216035A1 (es)
CN (1) CN102316881B (es)
AU (1) AU2010213010B2 (es)
BR (1) BRPI1008327A2 (es)
CL (1) CL2011001937A1 (es)
MX (1) MX2011008400A (es)
WO (1) WO2010091993A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140086954A1 (en) * 2011-03-31 2014-03-27 Chu De Toulouse Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
RU2015122728A (ru) 2012-11-12 2017-01-10 Компани Жервэ Данон Штамм lactobacillus rhamnosus для уменьшения накопления жира в организме
JP2016501010A (ja) * 2012-11-12 2016-01-18 コンパニ・ジェルベ・ダノンＣｏｍｐａｇｎｉｅ Ｇｅｒｖａｉｓ Ｄａｎｏｎｅ 体重増加及び／又はインスリン抵抗性を低減させるためのラクトバチルスラムノサス株の使用
CA2907526A1 (en) * 2013-03-28 2014-10-02 Nestec S.A. Alpha-keto-isovalerate as a biomarker of prebiotic efficacy for weight gain prevention
FR3004621B1 (fr) * 2013-04-19 2015-05-15 Gervais Danone Sa Souche de lactobacillus rhamnosus regulatrice du metabolisme lipidique
WO2015159125A1 (en) * 2014-04-15 2015-10-22 Compagnie Gervais Danone Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after antibiotic dysbiosis
CN103947962B (zh) * 2014-05-09 2015-10-28 上海盛世中侬农业科技发展有限公司 一种减肥食品
KR102125548B1 (ko) 2015-02-10 2020-06-24 주식회사 지니스 비만 억제능을 갖는 균주 및 이를 함유하는 약학 조성물
AU2016305391B2 (en) * 2015-08-12 2019-01-17 Cj Cheiljedang Corporation Novel Lactobacillus sp. microorganisms, and composition for animal feed comprising same
CN109757730B (zh) * 2019-01-31 2021-06-04 山东环亿生物科技有限公司 一种具有降血脂、血压以及血糖的组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
CN1638650A (zh) * 2001-03-09 2005-07-13 雀巢制品公司 改善与年龄有关的生理缺陷并延长寿命的组合物
US20040001898A1 (en) * 2002-06-26 2004-01-01 Armand Malnoe Compositions and methods for detoxification and cancer prevention
US7001756B1 (en) 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
CN100396770C (zh) 2004-03-19 2008-06-25 景岳生物科技股份有限公司 新的微生物鼠李糖乳杆菌gm-020及其治疗肥胖的用途
KR100686557B1 (ko) 2004-08-16 2007-02-23 씨제이 주식회사 체지방 저하 기능성 락토바실러스 람노서스와 이를 함유한 식품
EP1974734A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity

Also Published As

Publication number Publication date
EP2216035A1 (en) 2010-08-11
MX2011008400A (es) 2011-09-01
AU2010213010A1 (en) 2011-08-25
AU2010213010B2 (en) 2014-10-30
CN102316881B (zh) 2013-08-07
US20110293569A1 (en) 2011-12-01
BRPI1008327A2 (pt) 2016-02-23
WO2010091993A1 (en) 2010-08-19
US8318150B2 (en) 2012-11-27
CN102316881A (zh) 2012-01-11
EP2396012A1 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
CL2011001939A1 (es) Uso de lactobacillus helveticus cncm i-4095 para apoyar la perdida de peso y/o mantenimiento del peso en humanos y/o animales, particularmente para tratar la obesidad y trastornos metabólicos; y microorganismo de la cepa de lactobacillus helveticus cncm i-4095.
ES2561253T3 (es) Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
ES2491619T3 (es) Uso de bacterias coliformes productoras de gas inhibidoras de lactobacilos aisladas a partir de lactantes afectados por cólicos
IN2012DN02463A (es)
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
ES2531193T3 (es) Cepas de levadura y métodos de utilización de las mismas
BRPI1009263A2 (pt) alfa-amilases relacionadas com cepa de bacillus megaterium dsm90 e métodos de uso das mesmas.
ES2524432T3 (es) Bacterias del ácido láctico como cepas probióticas y composiciones que contienen las mismas
AR070984A1 (es) Cepa de lactobacillus rhamnosus
BR112015025256A8 (pt) Cepas probióticas para uso no tratamento ou prevenção da osteoporose
AR094025A1 (es) Utilizacion de bifidobacterium animalis para el tratamiento o la prevencion de la ganancia de peso corporal y de la resistencia a la insulina
MX2018006905A (es) Bifidobacterium longum para el tratamiento de la obesidad y trastornos metabolcos asociados.
MX2011008400A (es) Lactobacillus rhamnosus cncm i-4096 y el control del peso.
UA113399C2 (xx) Штам непатогенної грамнегативної бактерії та його застосування в дерматології
UA118339C2 (uk) Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
PH12015500091B1 (en) Non-pathogenic f18 e.coli strain and use thereof
MX2015005898A (es) Uso de una cepa de lactobacillus rhamnosus para reducir la ganancia de peso o la resistencia a la insulina, o ambas cosas al mismo tiempo.
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
AR093425A1 (es) Cepa de lactobacillus rhamnosus para reducir la acumulacion de grasa corporal
ES2663096T3 (es) Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas
IN2015DN03944A (es)
PL391623A1 (pl) Nowy szczep bakterii mlekowych Lactobacillus brevis
CL2012000012A1 (es) Bifidobacterium longum con número de depósito ncc2916; composición que lo comprende; uso de dicho bifidobacterium para aumentar el número de bacterias probióticas vivas en un producto.
PL410460A1 (pl) Biopreparat do konserwowania surowców odnawialnych przeznaczonych do produkcji biogazu
UA90976C2 (ru) Штамм br-06 реовируса кур для изготовления инактивированных вакцын против реовирусной инфекции кур